SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+11.17%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$900M
AUM Growth
+$900M
(+11%)
Cap. Flow
-$78M
Cap. Flow
% of AUM
-8.67%
Top 10 Holdings %
Top 10 Hldgs %
42.92%
Holding
115
New
38
Increased
26
Reduced
29
Closed
13
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$32M |
| 2 |
United Therapeutics
UTHR
|
$23.5M |
| 3 |
Humana
HUM
|
$17.4M |
| 4 |
Surmodics
SRDX
|
$13.9M |
| 5 |
The Beauty Health Co
SKIN
|
$11.6M |
Top Sells
| 1 |
GeneDx Holdings
WGS
|
$103M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$51.8M |
| 3 |
Exact Sciences
EXAS
|
$36.3M |
| 4 |
Smith & Nephew
SNN
|
$15.5M |
| 5 |
SI-BONE Inc
SIBN
|
$11.7M |
Sector Composition
| 1 | Healthcare | 96.82% |
| 2 | Consumer Staples | 2.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$13.8B
| $53.6M | 5.96% | 242,735 +106,500 | +78% | +$23.5M |
|
|
EDAP
2
EDAP TMS
EDAP
$84.5M
| $50.5M | 5.61% | 5,474,222 +162,000 | +3% | +$1.49M |
|
3
Charles River Laboratories
CRL
$8.04B
| $44M | 4.9% | 209,496 +53,400 | +34% | +$11.2M |
|
|
4
Surmodics
SRDX
$487M
| $41.9M | 4.65% | 1,336,838 +444,160 | +50% | +$13.9M |
|
5
Organogenesis Holdings
ORGO
$653M
| $38.9M | 4.33% | 11,728,063 +1,875,000 | +19% | +$6.23M |
|
6
iRadimed
IRMD
$921M
| $36.9M | 4.11% | 773,694 | – | – |
|
|
7
Teva Pharmaceuticals
TEVA
$21.1B
| $32M | 3.56% | +4,250,000 | New | +$32M |
|
8
Arcellx
ACLX
$3.85B
| $31.7M | 3.52% | 1,001,999 -246,148 | -20% | -$7.78M |
|
9
Vaxcyte
PCVX
$4B
| $28.5M | 3.17% | 571,250 +191,000 | +50% | +$9.54M |
|
|
10
Humana
HUM
$36.5B
| $28.1M | 3.12% | 62,750 +39,000 | +164% | +$17.4M |
|
11
CVS Health
CVS
$92.8B
| $24.5M | 2.73% | 355,054 +111,500 | +46% | +$7.71M |
|
12
Celcuity
CELC
$2.17B
| $21.1M | 2.35% | 1,923,283 +235,350 | +14% | +$2.58M |
|
|
13
The Beauty Health Co
SKIN
$264M
| $20.8M | 2.31% | 2,481,789 +1,391,837 | +128% | +$11.6M |
|
14
Rigel Pharmaceuticals
RIGL
$697M
| $18.3M | 2.03% | 14,178,015 +1,375,000 | +11% | +$1.77M |
|
|
15
SI-BONE Inc
SIBN
$719M
| $16.9M | 1.88% | 626,144 -434,839 | -41% | -$11.7M |
|
16
Axogen
AXGN
$743M
| $16.3M | 1.82% | 1,789,998 +10,000 | +0.6% | +$91.3K |
|
|
17
Smith & Nephew
SNN
$16.3B
| $15.8M | 1.75% | 489,268 -480,932 | -50% | -$15.5M |
|
|
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
| $13.7M | 1.52% | 71,000 | – | – |
|
19
BioAtla
BCAB
$26.7M
| $13M | 1.44% | 4,321,197 | – | – |
|
20
Krystal Biotech
KRYS
$4.27B
| $12.9M | 1.44% | 110,192 +25,013 | +29% | +$2.94M |
|
|
INBX
21
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $12.3M | 1.37% | 473,183 +35,181 | +8% | +$913K |
|
22
ESSA Pharma
EPIX
$11.4M
| $11.3M | 1.26% | 4,202,094 +56,977 | +1% | +$154K |
|
23
Neuropace
NPCE
$303M
| $11.1M | 1.23% | 2,466,214 +37,500 | +2% | +$168K |
|
24
TG Therapeutics
TGTX
$4.65B
| $10.8M | 1.2% | 435,500 -314,800 | -42% | -$7.82M |
|
25
Jasper Therapeutics
JSPR
$45.5M
| $10.7M | 1.18% | 7,775,980 +321,000 | +4% | +$440K |
|